Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic caffeine for preterm neonates with respiratory distress syndrome on nasal CPAP
IRCT20170627034782N2Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of caffeine in respiratory distress syndrome (RDS) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Duration of respiratory support with oxygen and CPAP. Started Nov 2019; status: completed.
02
Drugs
caffeine
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on IRCT20170627034782N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170627034782N2.